Journal Pre-proof

SARS-CoV-2 vaccine research and development: conventional vaccines and biomimetic nanotechnology strategies

Lanxiang Huang , Yuan Rong , Qin Pan , Kezhen Yi , Xuan Tang , Qian Zhang , Wei Wang , Jianyuan Wu , Fubing Wang

Please cite this article as: Lanxiang Huang , Yuan Rong , Qin Pan , Kezhen Yi , Xuan Tang , Qian Zhang , Wei Wang , Jianyuan Wu , Fubing Wang , SARS-CoV-2 vaccine research and development: conventional vaccines and biomimetic nanotechnology strategies, *Asian Journal of Pharmaceutical Sciences* (2020), doi: https://doi.org/10.1016/j.ajps.2020.08.001

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

SARS-CoV-2 vaccine research and development: conventional vaccines and biomimetic nanotechnology strategies

Lanxiang Huang [1,#], Yuan Rong[1,#], Qin Pan[2], Kezhen Yi [1], Xuan Tang[1], Qian Zhang[1], Wei Wang[1], Jianyuan Wu[3,**], Fubing Wang[1,*]

1. Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.

2. State Key Laboratory of Virology and Medical Research Institute, Hubei Province Key Laboratory of Allergy and Immunology and Department of Immunology, Wuhan University School of Basic Medical Sciences, Wuhan 430071, China.

3. Clinical Trial Center of Zhongnan Hospital, Wuhan University, Wuhan 430071, China.

[#] These authors contribute equally to this work

[*]**Corresponding author.** Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University, No.169 Donghu Road, Wuchang District, Wuhan 430071, China. Tel.: +86 27 67813517.

[**]**Corresponding author.** Clinical Trial Center of Zhongnan Hospital, Wuhan University, No.169 Donghu Road, Wuchang District, Wuhan 430071, China.

Email: wfb20042002@sina.com (F.B. Wang); wujianyuan@znhospital.com (J.Y. Wu)

Abstract

The development of a massively producible vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus, is essential for stopping the current coronavirus disease (COVID-19) pandemic. A vaccine must stimulate effective antibody and T cell responses *in vivo* to induce long-term protection. Scientific researchers have been developing vaccine candidates for the severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) since the outbreaks of these diseases. The prevalence of new biotechnologies such as genetic engineering has shed light on the generation of vaccines against novel viruses. In this review, we present the status of the development of coronavirus vaccines, focusing particularly on the biomimetic nanoparticle technology platform, which is likely to have a major role in future developments of personalized medicine.

Keywords:

SARS-CoV-2; COVID-19; Vaccine; Biomimetic nanotechnology; Virus-like nanoparticles

1. Introduction

The coronavirus disease (COVID-19) outbreak started in China at the end of 2019. As of April 30, 2020, there were 84,369 confirmed cases in China and 3,077,229 confirmed cases outside of China [1]. The outbreak and current pandemic have attracted worldwide attention following the WHO's declaration that the outbreak was a global health emergency. The widespread and severe clinical impact of COVID-19 compelled the Chinese government to take strict measures to prevent the spread of the virus [2]. In addition to the development of therapeutic agents against SARS-CoV-2, there is an urgent need to development an efficacious vaccine to combat the rapid spread of SARS-CoV-2. Since the birth of the first vaccine in 1796, vaccines have profoundly reduced the prevalence and fatality rates of various infectious diseases, including measles and smallpox [3]. Owing to rapid advances in technology, novel materials have been employed for vaccine preparation, such as virus-like particles (VLPs). For example, a VLP-based HPV vaccine, which is now commercially available, has improved HPV prevention.

Coronavirus is a type of single-stranded RNA virus that contains four main structural proteins including a phosphorylated nucleocapsid (N) protein, two types of spike (S) proteins, a membrane (M) protein, and an envelope (E) protein [4].

SARS-CoV-2 S proteins bind to angiotensin converting enzyme 2 (ACE2) to enter human cells [5, 6]. A recent study revealed the high-resolution structure of SARS-CoV-2 S proteins [6], and has therefore provided valuable clues for the development of SARS-CoV-2 vaccines and therapies. Owing to the similarities of the structure of SARS-CoV-2, SARS-CoV, and MERS-CoV as well as common symptoms of the patients infected with these viruses, studies on SARS-CoV and MERS-CoV may support future studies on SARS-CoV-2 [7, 8]. Researchers have proposed several SARS-CoV and MERS-CoV vaccine candidates including inactivated vaccines, live-attenuated vaccines, and viral-vector vaccines, etc. [9] (Table 1). Importantly, emerging genetic engineering methods and nanotechnology have revolutionized vaccine development. Biomimetic nanoparticle-based vaccines have become attractive, alternative strategies for the prevention of diseases. We analyzed conventional coronavirus vaccines against COVID-19, and have discussed the possible application of biomimetic nanoparticles such as VLPs in the development of SARS-CoV-2 vaccines.

2. Conventional coronavirus vaccines

Conventional coronavirus vaccines include inactivated vaccines, live-attenuated vaccines, viral vector vaccines, subunit vaccines, and nucleic acid vaccines.

2.1 Inactivated vaccine

Inactivated vaccines are viral particles killed by irradiation or chemicals. Their production is relatively easy, and they induce a robust immune response owing to the multiple epitopes on the viral surface [9]. However, it is reported that SARS-CoV inactivated vaccine increase eosinophilic pro-inflammatory pulmonary response upon challenge [24, 25]. Studies have shown that SARS-CoV N protein vaccination enhances the immunopathological changes in the lungs. SARS-CoV N protein-specific T cells and Th2-skewed cytokine profile may be the cause of adverse reactions [26, 27]. Therefore, it is necessary to find methods to enhance the protective

S-specific immune response while minimizing the potentially pathological anti-N response. We should keep in mind that the side effects of inactivated vaccines must be intensively evaluated before clinical application. Furthermore, most research on coronavirus must be performed cautiously in biosafety level-3 (BSL-3) laboratories, which has hindered the development of coronavirus vaccines.

Inactivated SARS-CoV vaccines induce the production of high levels of specific neutralizing antibodies in animal models [10, 28, 29], including antibodies against the viral S, N and M proteins. The results from *in vivo* experiments showed that the levels of antibodies against the N and S proteins were higher than the levels of antibodies against M proteins in antisera from vaccinated mice, suggesting that epitope polypeptides from the N or S proteins may be potential targets for the generation of recombinant SARS vaccines [10]. On April 12, 2020, the inactivated SARS-CoV-2 vaccine developed in Wuhan, China was approved for clinical trials, it is the world's first inactivated SARS-CoV-2 vaccine to enter clinical trials [30]. The inactivated SARS-CoV-2 vaccine is currently in Phase II clinical trials.

2.2 Live-attenuated vaccine

Live-attenuated vaccines are created by weakening infectious organisms that can still replicate and induce protective immune responses, but do not cause disease in the host. The live-attenuated vaccine against coronavirus may be generated by depleting or mutating virulent genes in the viral genome. These live-attenuated vaccines diminish virulence while maintaining immunogenicity. Live-attenuated vaccines are good at driving both innate and adaptive immunity with long-term immunological memory. Furthermore, these vaccines can be produced quickly and at a low cost, thus, they are ideal for responding to coronavirus outbreaks [31]. Researchers have generated a series of live-attenuated SARS or MERS vaccine candidates that have successfully induced immune responses *in vivo* [24, 32-35]. However, it is vital to avoid the restoration of virulence in these vaccines owing to the back-mutation of attenuating mutations, compensatory mutations elsewhere in the genome,

recombination or reassortment.

2.3 Viral vector vaccine

Viral vector vaccines use live recombinant viruses to deliver DNA into human cells. The DNA sequences loaded into the viral vector vaccines encode one or more antigens. After these vector vaccines infect cells, the antigen protein is expressed in the cells, and the antigen is processed to activate the subsequent immune response (Fig. 1). Several viral vectors have been used to construct coronavirus vaccines, including measles virus, vaccinia virus Ankara (MVA), and recombinant adenovirus vectors (ADVs). The genes encoding the N protein and the S protein have been loaded into the viral vectors to trigger anti-coronavirus immunity in the host [17, 18, 36-40]. The effectiveness of SARS and MERS viral vector vaccines have been validated in animal models. These viral vector vaccines are capable of triggering specific CD8$^+$ T cell response and generating high levels of virus-neutralizing antibodies.

Adenovirus vectors are the most commonly used vectors in clinical trials [41]. They are widely used in gene therapy, vaccination and other fields. It is one of the best candidates for vaccine development, mainly owing to its low pathogenicity, genetic safety, lack of host genome integration steps in its replication cycle, and induction of strong humoral and cellular immune responses. Adenovirus type-5 (Ad5) vector is the most commonly used vector. Ad5 vector vaccines against human immunodeficiency virus type 1 (HIV-1) and Ebola virus have been investigated in Phase II clinical trials to verify their safety and effectiveness [42, 43]. For other pathogens, recombinant adenovirus type 5 (rAd5) vector vaccines have also elicited antigen-specific cellular immune responses [44]. Professor Wei Chen and colleagues reported the safety, tolerability and immunogenicity of a rAd5 vectored COVID-19 vaccine in The Lancet [45]. Using genetic engineering technology, replication-deficient Ad5 was used as a vector to prepare a vaccine that expresses the SARS-CoV-2 S protein.

However, adenovirus infection induces a strong innate and adaptive immune response and establishes long-term immune memory. Ad5 is a common human serotype and has a high infection rate, as such, anti-Ad5 antibodies may already be present in the human body, especially in individuals in developing countries [46-48]. Thus, the immunogenicity and clinical utility of the Ad5 vector vaccine is limited. Research has shown that a homologous priming-boosting regimen with an Ad-5-type vaccine at 6-month intervals was able to elicit strong antibody responses with a longer duration [49]. The results supported the use of an immunization strategy to implement a booster injection to effectively overcome the effect of pre-existing immunization on vaccine efficacy. This indicated that the clinical trial of Ad5-nCoV may also require a strategy that uses a booster injection.

Existing immunity to Ad5 in humans is highly prevalent, consequently, this has led to the development of vectors derived from rare Ad serotypes. Ad26 vectors have been proven to have the highest immunogenicity of the rare serotype Ad vectors studied, which has shown the potential of the Ad26 as a vaccine vector in developing countries [50]. Another company has developed a vaccine based on Ad26 vector, the company expects to initiate human clinical studies of its lead vaccine candidate by September 2020 at the latest and anticipates the first batches of a SARS-CoV-2 vaccine could be available for emergency use authorization in early 2021 [51]. The company's research strategy is promising.

2.4 Subunit vaccine

A subunit vaccine is a vaccine produced from selected viral antigenic protein subunits. Thus, this type of vaccine has a lower risk of adverse reactions compared with a whole virus vaccine. Subunit vaccines for the S protein fragment of SARS-CoV and MERS-CoV have been reported previously [52, 53]. However, the MERS-CoV S protein likely contains non-neutralizing epitopes, which may hinder the production of neutralizing antibodies and the anti-MERS-CoV immune responses. Therefore, it is necessary to identify the critical neutralizing epitopes in the

MERS-CoV S protein and exclude non-neutralizing epitopes without the expense of domain integrity and stability in the design of the subunit vaccine for inducing the host immune response [54]. The spike glycoprotein of MERS-CoV is a type I trimeric membrane protein expressed on the viral surface. It binds to dipeptidyl peptidase 4 (DPP4) on target cells [55]. Currently, the neutralizing epitopes and functional mechanisms of monoclonal antibodies including 4C2, 2E6, 7D10, D12, m336, MCA1, MERS-27, JC57-14, CDC-C2, MERS-4, and MERS-GD27 were elucidated at the atomic level by structural and functional studies [56-58]. These antibodies target the receptor-binding subdomain of MERS-CoV and overlap with the DPP4 binding surface. These studies are the basis for the development of subunit vaccines.

2.5 Nucleic acid vaccine

Nucleic acid vaccines include DNA vaccines and mRNA vaccines. After nucleic acid vaccines are inoculated into the cells, the antigenic proteins encoded by the vaccines are expressed on the cells, and the immune system in the host stimulates specific immune reactions [59-61]. DNA vaccines are based on bacterial plasmid vectors that encode vaccine antigens driven by efficient eukaryotic promoters [62]. Application of a DNA vaccine encoding the MERS virus S protein is successful in Phase I clinical trial. Vaccine-induced humoral and cellular responses have been detected in the trial [63, 64]. Nucleic acid vaccines can be produced on a massive scale and could be easily purified from genetically modified bacteria. Consequently, nucleic acid vaccines may be ideal for the fast, inexpensive and large-scale preparation of SARS-CoV-2 vaccines. The DNA vaccine platform was one of the first technologies to receive support from the Coalition for Epidemic Preparedness Innovations (CEPI) to accelerate SARS-CoV-2 vaccine development. The SARS-CoV-2 vaccine candidate (INO-4800) is in Phase I/II clinical trials in South Korea and the United States [65].

Over the past decade, significant technological innovations and research

investments have made mRNA a promising therapeutic tool in the field of vaccine development and protein replacement therapy [66]. mRNA is the intermediate molecule between DNA and proteins. The mRNA vaccine aims to deliver antigen-encoding mRNA into the ribosome to produce viral antigens [67]. The mRNA vaccine is taken by different types of cells and activates the immune system through the MHC-I pathway and the MHC-II pathway after vaccination (Fig. 2). When the mRNA vaccine is taken by APCs, APCs processes and express the target protein as an endogenous antigen, and then activates CD8$^+$ T cells through the MHC-I pathway. When the mRNA vaccine is taken by non-APCs, the cells translate and secrete the target protein which is then taken by APC. The APCs subsequently activate CD4$^+$ T cells through the MHC-II pathway. Exogenous antigens can also be processed and loaded onto MHC-I molecules through cross-presentation [68].

mRNA-based vaccines are a promising new platform that is highly versatile, safe, effective, simplified, scalable and cheap, has the potential to be free of cold chains [67, 69, 70]. Importantly, mRNA-based vaccines can meet the requirement for rapid and large amounts of effective vaccines against emerging pandemic infectious diseases [67]. This multi-functional RNA vaccine platform can increase the speed and cost of vaccine development and quickly produce effective vaccines for new epidemics [71]. By optimizing the mRNA manufacturing platform and the design of intracellular delivery methods, the clinical transformation of mRNA therapy has been improved [72].

On January 13, 2020, the U.S. National Institutes of Health (NIH) finalized the sequence for a potential mRNA vaccine, mRNA-1273 [73]. mRNA-1273 is a vaccine that encodes for a prefusion stabilized form of the S protein of SARS-CoV-2. On March 16, 2020, the NIH announced that the first participant in its Phase I study for mRNA-1273 was dosed. The mRNA platform offers significant advantages in terms of speed and efficiency from the perspectives of basic science, manufacturing and clinical development.

3. Biomimetic nanotechnology in the development of vaccines

Although conventional viral vaccines have delivered considerable success, their ability to generate strong antiviral responses is limited and great challenges remain in achieving effective responses to sudden epidemics. Further, traditional vaccine preparation methods cannot produce vaccines against viruses with high antigen diversity and mutation rates, thereby limiting the development of vaccines. To address these obstacles with conventional vaccines, many researchers have turned to nanotechnology to design and produce nanoparticle vaccines with good effectiveness, specificity and long-lasting antiviral response. Taking the VLP vaccine as an example, highly conserved antigens shared by different virus subtypes can be inserted into VLPs as potent antigenic proteins [74]. Structural informatics can be used to reconstruct and modify conserved epitopes to expose highly immunogenic regions or insert multiple immunodominant epitopes into the same VLP to create a broadly cross-protective vaccine [75]. This is of great significance for viruses that exhibit highly variable antigenicity and enormous mutations.

Biomimetic nanoparticle technology, a novel type of nanotechnology, is a rapidly developing field that has undergone tremendous advances in the last decade. Taking advantage of the specific delivery and translocation mechanisms adopted by pathogens, bioinspired nanoparticles have been produced with diverse functions, good biocompatibility, extended circulation time and enhanced accumulation at the infection sites [76]. Biomimetic nanoparticles have unique antigenic characteristics and immunostimulatory properties and have been used to design more effective vaccine formulations. This strategy directly uses the principles of natural design to manufacture multifunctional and multi-antigen nanosystems that may play an important role in the future [77, 78]. Compared with traditional vaccines, the careful manipulation of nanoparticle parameters and conscious design can yield significant improvements in efficacy.

3.1 Advantages of biomimetic nanoparticles for vaccine development

MERS-CoV-specific IgA protects patients with the infection, but cannot persist for a long period [79]. MERS-CoV-specific memory CD8$^+$ T cells can be detected in the body for up to 6 years and exert a strong antiviral effect on various subtypes of viruses [80, 81]. Live-attenuated vaccines are capable of inducing the formation of memory T cells. However, the potential risk of restoration of virulence hampers the application of conventional coronavirus vaccines in clinical trials. Therefore, non-live virus vaccines that robustly induce memory T cells are in great demand.

As next-generation medical agents, biomimetic nanoparticles simulate the physiochemical nature of the pathogens while retaining the surface features of nanoparticles [78]. Biomimetic nanoparticle vaccines usually consist of three elements: viral antigen molecules, adjuvants and a protein scaffold. The viral antigens induce the adaptive immune response, and the adjuvants enhance innate immune response [82-85]. This vaccine type is safer and more effective than conventional vaccines. Biomimetic nanoparticle delivery not only protects the adjuvant from degradation but also protects the body from systemic toxicity caused by free adjuvants, which may cause side effects such as fever, drowsiness, diarrhea, and nausea [86]. Current biomimetic nanoparticles available for vaccine preparation include virosomes, VLPs, self-assembling protein nanoparticles and synthetic nanoparticles, with sizes ranging from 10 to 200 nm [76, 87]. VLPs are the most frequently used biomimetic nanoparticles in vaccine preparation. VLPs carry both antigens and adjuvants [88], and prime immune cells to induce immune responses after vaccination.

3.2 Immune responses induced by biomimetic nanoparticle vaccines

VLP vaccines are capable of conferring humoral immune responses and triggering the production of neutralizing antibodies (Fig. 3). B cells specifically bind to the antigens carried by VLPs through B cell receptors (BCRs) and internalize VLPs. The recognition and internalization of VLP vaccines provide signals for B cell activation. Consequently, activated B cells initially differentiate into plasmablasts and ultimately

into plasma cells to produce antibodies [89] including IgG and IgA [90]. Under the induction of T follicular helper cells (TFH), memory B cells and plasmacytes are produced and sustained in the germinal centers [91].

VLP vaccines also activate the cell-mediated immune response (Fig. 3). The maturation of dendritic cells (DCs) is critical to successfully trigger cellular the immune response induced by a vaccine. DC maturation requires both antigen presentation and co-stimulatory molecules. Antigens are engulfed and processed by DCs, subsequently, the antigenic peptide binds to MHC molecules and is presented on the surface of DCs. T cells will be activated by recognizing the antigenic peptides presented by MHC molecules, as well as by binding to c molecules on DCs. The adjuvants in biomimetic nanoparticle vaccines act as costimulatory molecules, whereas viral proteins provide antigens. These interactions between VLP vaccines and DCs induce maturation of DCs and the subsequent T cell activation [92, 93], including the activation of both helper T (Th) cells and cytotoxic T lymphocytes (CTLs) [94, 95]. Activated Th cells induce cytokines to promote antiviral immunity and to upregulate the expression of costimulatory molecules for B cell activation and differentiation into plasma cells. CTLs inhibit virus replication by lysing infected cells to release the virus and neutralizing antibodies to destroy the virus.

Therefore, biomimetic nanoparticle vaccines provide sufficient stimulatory signals to launch both cellular and humoral immunity.

3.3 VLPs for vaccine development

VLPs are the noninfectious protein shells or capsids conjugated with virus-derived structural proteins that are modified to be of use in nanotechnology. The structure of VLPs is similar to natural viruses but has no viral genome. VLPs are strongly immunogenic and biologically active [96], capable of inducing both cellular and humoral immune reactions [97, 98]. VLPs' sizes range from 20 to 100 nm [99]. In comparison with conventional virus vaccines such as inactive or live-attenuated vaccines, VLPs are much safer and can be more easily produced at a lower cost.

VLPs have more diverse immunogenicity than subunit vaccines and nucleic acid vaccines [100, 101].

Evidence has accumulated to show that VLPs promote protective immunity against infectious diseases including flu, hand, foot, and mouth disease, hepatitis B, and HPV infection [98, 102-106]. The immunogenicity of HBV VLP was significantly higher than the recombinant protein vaccine. HBV VLP elicits neutralizing antibodies and is capable of stimulating specific $CD8^+$ and $CD4^+$ T cell responses *in vivo* [107]. VLPs may also be used as a potential therapeutic vaccine owing to their powerful effect on the induction of antiviral immunity [108]. Some VLP vaccines for HPV are already commercially available, including Cervarix®, Gardasil®, and Gardasil9®, and Sci-B-Vac™ is an HBV vaccine [102, 105, 109]. VLPs are generated in insect or yeast expression systems, which can express complex viral protein antigens on a large scale for commercial purposes [110].

VLPs vaccines are considered to be a powerful candidate for the prevention of the SARS-CoV-2 pandemic. VLP-based coronavirus vaccines have previously been developed using a variety of antigen combinations or expression systems. These vaccines are reported to inhibit coronavirus infections and are thus promising or future clinical applications [111-119]. However, to date, few studies have investigated whether the combination of VLPs with adjuvants enhanced the protective effects of VLP-based vaccines. A research team uses its proprietary recombinant protein nanoparticle technology platform to develop a SARS-CoV-2 vaccine candidate containing the coronavirus S protein. They recommend utilizing its proprietary Matrix-M™ adjuvant to enhance immune responses during the vaccination with the vaccine. It is expected to advance the SARS-CoV-2 vaccine candidate to Phase I clinical testing in May or June [120].

3.4 Modification of VLPs

Researchers are attempting to modify the surface of VLPs with small molecules or chemical groups to protect the "cargo" from the negative effects of enzymes or serum

proteins and increase the targeting accuracy [121]. This approach has been evaluated in tumor therapy. However, the necessity of surface modification to VLP-based vaccines remains controversial. VLPs have a unique repetitive surface structure that is easily recognized by the innate immune system. This structure is the basis of VLPs' strong immunogenicity because it induces the opsonization of antigen-presenting cells [121]. Moreover, this structure promotes B-cell activation, resulting in a stronger humoral immune response, as well as enhanced T-cell stimulation and cellular mediated immunity [122]. Therefore, it may be unnecessary to increase the uptake of VLPs by modifying the surface of VLPs.

VLPs are able to spontaneously assemble nucleic acids, enabling them to effectively deliver CpG [123]. Cytidine monophosphate guanosine oligodeoxynucleotides (CpG or CpG ODN) are a class of DNA analog composed of unmethylated cytosine. As a robust adjuvant, CpG-ODN binds to TLR9 to trigger the maturation of antigen presenting cells, resulting in the promotion of $CD4^+$ and $CD8^+$ T cell responses, as well as B cell activation and proliferation. Consequently, both T cell response and antibody production are conferred to provide comprehensive protection of immunized individuals from virus infection [124-129]. The CpG adjuvanted VLP vaccines were shown to enhance cellular immunity in preclinical models of infections for the foot-and-mouth-disease virus and influenza virus [130, 131]. The combination of a CpG adjuvant is an important strategy to enhance the efficacy, potency, and safety of VLP vaccines.

4. Perspectives

We have proposed a promising strategy for the development of a novel SARS-CoV-2 vaccine: biosynthetic SARS-CoV-2 VLPs combined with CpG (termed CpG-VLP SARS-CoV-2 vaccine). Most vaccines consist of antigens and immune adjuvants, it is the spatial colocalization of these two components that ensures a prompt immune response against the antigen of interest [132]. VLP-based SARS-CoV-2 vaccines may show advantages in the induction of persistent immune

reactions for the prevention of SARS-CoV-2 infection. In the face of a rapidly emerging epidemic, reduction of vaccine development time and costs is important. Existing vaccine technology cannot quickly respond to new virus outbreaks; thus, further developments are required to address practicality at the industrial scale. VLP platform technology has the potential to address the rapid spread of emerging viruses.

VLP technology can overcome numerous drawbacks associated with traditional methods of vaccine production, such as infectiousness and lengthy production time. The yield and cost of the vaccine depend on the choice of expression systems and the purification process. VLP technology is rapidly developing especially in the optimization of the expression system and VLP purity. For example, for the expression system, a study reported that when produced in *E. coli*, the murine polyomavirus (MuPyV) capsomere platform was capable of producing 320 million vaccine doses in a few days, at a low cost. This shows its suitability as a rapid response and low-cost vaccine platform [133]. The recently optimized Insect Cell-Baculovirus Expression Vector System (IC-BEVS) has a similar potential [134]. IC-BEVS is used to manufacture approved VLP vaccines such as Cervarix® and Porcilis PCV®. The purification of VLPs is usually performed via polyethylene glycol precipitation, diafiltration, chromatography, density gradient ultracentrifugation, ultracentrifugation or continuous flow ultracentrifugation [135, 136]. Although these technologies are widely used, they have the following disadvantages: the inability to remove host cell-derived contaminants, the rupture of particles that affect immunogenicity, the expensive equipment required for continuous flow ultracentrifugation, and the potentially hazardous materials generated by viral ultracentrifugation [137]. Chromatography is still used in industry to purify VLP vaccines, but this method is time-consuming and costly. There is still a need to develop more efficient and cost-effective purification methods. The purification method based on sulfated cellulose membrane adsorbers is significantly better than the traditional method [138]. As it is easy to popularize and simplifies the purification steps, it can be used as a general purification platform for VLP vaccines, and this

technology is expected to be used to purify VLPs on a large scale.

The clinical transformation of vaccines depends on the mature vaccine production process to ensure a stable and reliable vaccine supply and to expand vaccine production in a safe, effective, and cost-effective manner. As a non-infectious universal vaccine platform, VLPs are easy to standardize in the production process of vaccines and to minimize the unstable factors in the production process to achieve the rapid production of safe and cheap vaccines. Regulatory agencies manage each stage of vaccine production to ensure high-quality and consistent products. In the future, mechanistic studies should be conducted to examine the biological mechanism and the *in vivo* pharmacokinetic profiles of biomimetic nanoparticles. There is still a need to explore better-optimized expression systems and purification methods to actualize high-throughput production. Standardized work processes also need to be consistent with good manufacturing practices to meet the quality requirements approved by regulatory authorities. Simultaneously, VLP characterization is a key step to ensure the stability and effectiveness of VLP vaccines. The development of rapid analysis methods that can support the analysis of a large number of VLPs will help more effective vaccine development.

Acknowledgments

Conflicts od interests

The authors have declared that no competing interest exists.

References

1. World Health Organization. Coronavirus disease 2019 (COVID-19) situation reports 1-99. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.

2. Deng SQ, Peng HJ. Characteristics of and public health responses to the coronavirus disease 2019 outbreak in China. J Clin Med 2020; 9: 575.

3. Justiz Vaillant AA GM. Vaccine (Vaccination). StatPearls; 2020.

4. Masters PS. The molecular biology of coronaviruses. Adv Virus Res 2006; 66: 193-292.

5. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020; 367: 1260-3.

6. Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci 2020; 63: 457-60.

7. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382: 727-33.

8. Chan JFW, Yuan S, Kok KH, To KKW, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020; 395: 514-23.

9. Reperant LA, Osterhaus ADME. AIDS, Avian flu, SARS, MERS, Ebola, Zika… what next? Vaccine 2017; 35: 4470-4.

10. Xiong S, Wang YF, Zhang MY, Liu XJ, Zhang CH, Liu SS, et al. Immunogenicity of SARS inactivated vaccine in BALB/c mice. Immunol Lett 2004; 95: 139-43.

11. Takasuka N, Fujii H, Takahashi Y, Kasai M, Morikawa S, Itamura S, et al. A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice. Int Immunol 2004; 16: 1423-30.

12. Qin E, Shi H, Tang L, Wang C, Chang G, Ding Z, et al. Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine. Vaccine 2006; 24: 1028-34.

13. Deng Y, Lan J, Bao L, Huang B, Ye F, Chen Y, et al. Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of Middle East respiratory syndrome coronavirus. Emerg Microbes Infect 2018; 7: 60.

14. Tai W, Wang Y, Fett CA, Zhao G, Li F, Perlman S, et al. Recombinant receptor-binding domains

of multiple Middle East respiratory syndrome coronaviruses (MERS-CoVs) induce cross-neutralizing antibodies against divergent human and camel MERS-CoVs and antibody escape mutants. J Virol 2016; 91: e01651-16.

15. Fett C, DeDiego ML, Regla-Nava JA, Enjuanes L, Perlman S. Complete protection against severe acute respiratory syndrome coronavirus-mediated lethal respiratory disease in aged mice by immunization with a mouse-adapted virus lacking E protein. J Virol 2013; 87: 6551-9.

16. Lamirande EW, DeDiego ML, Roberts A, Jackson JP, Alvarez E, Sheahan T, et al. A live attenuated severe acute respiratory syndrome coronavirus is immunogenic and efficacious in golden Syrian hamsters. J Virol 2008; 82: 7721-4.

17. Veit S, Jany S, Fux R, Sutter G, Volz A. CD8+ T Cells Responding to the Middle East respiratory syndrome coronavirus nucleocapsid protein delivered by vaccinia virus MVA in mice. Viruses 2018; 10: 718.

18. Volz A, Kupke A, Song F, Jany S, Fux R, Shams-Eldin H, et al. Protective efficacy of recombinant modified vaccinia virus ankara delivering Middle East respiratory syndrome coronavirus spike glycoprotein. J Virol 2015; 89: 8651-6.

19. Guo X, Deng Y, Chen H, Lan J, Wang W, Zou X, et al. Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus. Immunology. 2015; 145: 476-84.

20. Adney DR, Wang L, van Doremalen N, Shi W, Zhang Y, Kong W-P, et al. Efficacy of an adjuvanted Middle East respiratory syndrome coronavirus spike protein vaccine in dromedary camels and alpacas. Viruses 2019; 11: 212.

21. Lan J, Deng Y, Chen H, Lu G, Wang W, Guo X, et al. Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen. PLoS One 2014; 9: e112602.

22. Al-Amri SS, Abbas AT, Siddiq LA, Alghamdi A, Sanki MA, Al-Muhanna MK, et al. Immunogenicity of candidate MERS-CoV DNA vaccines based on the spike protein. Sci Rep 2017; 7: 44875.

23. Muthumani K, Falzarano D, Reuschel EL, Tingey C, Flingai S, Villarreal DO, et al. A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Sci Transl Med 2015; 7: 301ra132.

24. Bolles M, Deming D, Long K, Agnihothram S, Whitmore A, Ferris M, et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J Virol 2011; 85:

12201-15.

25. Yasui F, Kai C, Kitabatake M, Inoue S, Yoneda M, Yokochi S, et al. Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV. J Immunol 2008; 181: 6337-48.

26. Deming D, Sheahan T, Heise M, Yount B, Davis N, Sims A, et al. Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Med 2006; 3: e525-e.

27. Yasui F, Kai C, Kitabatake M, Inoue S, Yoneda M, Yokochi S, et al. Prior Immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV. J Immunol 2008; 181: 6337.

28. Iwata-Yoshikawa N, Uda A, Suzuki T, Tsunetsugu-Yokota Y, Sato Y, Morikawa S, et al. Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine. J Virol 2014; 88: 8597-614.

29. Tsunetsugu-Yokota Y. Large-scale preparation of UV-inactivated SARS coronavirus virions for vaccine antigen. Methods Mol Biol 2008; 454: 119-26.

30. China National Biotec Corporation, Inc. The world's first inactivated novel coronavirus vaccine was approved by the State Drug Administration for clinical trials. Available from: https://www.cnbg.com.cn/content/details_12_5417.html.

31. Vignuzzi M, Wendt E, Andino R. Engineering attenuated virus vaccines by controlling replication fidelity. Nat Med 2008; 14: 154-61.

32. Chafekar A, Fielding BC. MERS-CoV: understanding the latest human coronavirus threat. viruses 2018; 10: 93.

33. Menachery VD, Gralinski LE, Mitchell HD, Dinnon KH, 3rd, Leist SR, Yount BL, Jr., et al. Combination attenuation offers strategy for live attenuated coronavirus vaccines. J Virol 2018; 92: e00710-8.

34. Zumla A, Chan JFW, Azhar EI, Hui DSC, Yuen KY. Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov 2016; 15: 327-47.

35. Graham RL, Becker MM, Eckerle LD, Bolles M, Denison MR, Baric RS. A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease. Nat Med 2012; 18: 1820-6.

36. Enjuanes L, Zuñiga S, Castaño-Rodriguez C, Gutierrez-Alvarez J, Canton J, Sola I. Molecular

basis of coronavirus virulence and vaccine development. Adv Virus Res 2016; 96: 245-86.

37. Shim BS, Stadler K, Nguyen HH, Yun CH, Kim DW, Chang J, et al. Sublingual immunization with recombinant adenovirus encoding SARS-CoV spike protein induces systemic and mucosal immunity without redirection of the virus to the brain. Virol J 2012; 9: 215.

38. Altenburg AF, Kreijtz JHCM, de Vries RD, Song F, Fux R, Rimmelzwaan GF, et al. Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases. Viruses 2014; 6: 2735-61.

39. Haagmans BL, van den Brand JMA, Raj VS, Volz A, Wohlsein P, Smits SL, et al. An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels. Science 2016; 351: 77-81.

40. Malczyk AH, Kupke A, Prüfer S, Scheuplein VA, Hutzler S, Kreuz D, et al. A highly immunogenic and protective Middle East respiratory syndrome coronavirus vaccine based on a recombinant measles virus vaccine platform. J Virol 2015; 89: 11654-67.

41. Arnberg N. Adenovirus receptors: implications for targeting of viral vectors. Trends Pharmacol Sci 2012; 33: 442-8.

42. Gray GE, Moodie Z, Metch B, Gilbert PB, Bekker LG, Churchyard G, et al. Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. Lancet Infect Dis 2014; 14: 388-96.

43. Zhu FC, Wurie AH, Hou LH, Liang Q, Li YH, Russell JBW, et al. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2017; 389: 621-8.

44. Liu J, Ewald BA, Lynch DM, Denholtz M, Abbink P, Lemckert AAC, et al. Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys. J Virol 2008; 82: 4844-52.

45. Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 2020; 395: 1845-54.

46. Abbink P, Lemckert AAC, Ewald BA, Lynch DM, Denholtz M, Smits S, et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 2007; 81: 4654.

47. Roberts DM, Nanda A, Havenga MJE, Abbink P, Lynch DM, Ewald BA, et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 2006; 441:

239-43.

48. Kostense S, Koudstaal W, Sprangers M, Weverling GJ, Penders G, Helmus N, et al. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS 2004; 18: 1213-6.

49. Li JX, Hou LH, Meng FY, Wu SP, Hu YM, Liang Q, et al. Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Glob Health 2017; 5: e324-34.

50. Abbink P, Lemckert AAC, Ewald BA, Lynch DM, Denholtz M, Smits S, et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 2007; 81: 4654-63.

51. Janssen Pharmaceuticals, Inc. Johnson & Johnson announces a lead vaccine candidate for COVID-19; Landmark new partnership with U.S. Department of Health & Human Services; and commitment to supply one billion vaccines worldwide for emergency pandemic use. Available from: https://www.jnj.com/johnson-johnson-announces-a-lead-vaccine-candidate-for-covid-19-landmark-new-partnership-with-u-s-department-of-health-human-services-and-commitment-to-supply-one-billion-vaccines-worldwide-for-emergency-pandemic-use.

52. Wang J, Tricoche N, Du L, Hunter M, Zhan B, Goud G, et al. The adjuvanticity of an O. volvulus-derived rOv-ASP-1 protein in mice using sequential vaccinations and in non-human primates. PLoS One 2012; 7: e37019.

53. Lan J, Yao Y, Deng Y, Chen H, Lu G, Wang W, et al. Recombinant receptor binding domain protein induces partial protective immunity in rhesus macaques against Middle East respiratory syndrome coronavirus challenge. EBioMedicine 2015; 2: 1438-46.

54. Ma C, Wang L, Tao X, Zhang N, Yang Y, Tseng CTK, et al. Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments--the importance of immunofocusing in subunit vaccine design. Vaccine 2014; 32: 6170-6.

55. Lu G, Hu Y, Wang Q, Qi J, Gao F, Li Y, et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 2013; 500: 227-31.

56. Li Y, Wan Y, Liu P, Zhao J, Lu G, Qi J, et al. A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein. Cell Res 2015; 25: 1237-49.

57. Zhang S, Zhou P, Wang P, Li Y, Jiang L, Jia W, et al. Structural definition of a unique neutralization epitope on the receptor-binding domain of MERS-CoV spike glycoprotein. Cell Rep 2018; 24: 441-52.

58. Zhou H, Chen Y, Zhang S, Niu P, Qin K, Jia W, et al. Structural definition of a neutralization epitope on the N-terminal domain of MERS-CoV spike glycoprotein. Nat Commun 2019; 10: 3068.

59. Armengol G, Ruiz LM, Orduz S. The injection of plasmid DNA in mouse muscle results in lifelong persistence of DNA, gene expression, and humoral response. Mol Biotechnol 2004; 27: 109-18.

60. Donnelly JJ, Wahren B, Liu MA. DNA vaccines: progress and challenges. J Immunol 2005; 175: 633-9.

61. Lutz J, Lazzaro S, Habbeddine M, Schmidt KE, Baumhof P, Mui BL, et al. Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines. NPJ Vaccines 2017; 2: 29.

62. Li L, Petrovsky N. Molecular mechanisms for enhanced DNA vaccine immunogenicity. Expert Rev Vaccines 2016; 15: 313-29.

63. Muthumani K, Falzarano D, Reuschel EL, Tingey C, Flingai S, Villarreal DO, et al. A synthetic consensus anti–spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Sci Transl Med 2015; 7: 301ra132.

64. Modjarrad K, Roberts CC, Mills KT, Castellano AR, Paolino K, Muthumani K, et al. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. Lancet Infect Dis 2019; 19: 1013-22.

65. INOVIO, Inc. IVI, INOVIO, and KNIH to partner with CEPI in Phase 1/2 Clinical Trial of INOVIO's COVID-19 DNA vaccine in South Korea; Available from: http://ir.inovio.com/news-and-media/news/press-release-details/2020/IVI-INOVIO-and-KNIH-to-Part ner-with-CEPI-in-Phase-12-Clinical-Trial-of-INOVIOs-COVID-19-DNA-Vaccine-in-South-Korea/def ault.aspx.

66. Schlake T, Thess A, Fotin-Mleczek M, Kallen KJ. Developing mRNA-vaccine technologies. RNA Biol 2012; 9: 1319-30.

67. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov 2018; 17: 261-79.

68. Wadhwa A, Aljabbari A, Lokras A, Foged C, Thakur A. Opportunities and challenges in the delivery of mRNA-based vaccines. Pharmaceutics 2020; 12: 102.

69. Alberer M, Gnad-Vogt U, Hong HS, Mehr KT, Backert L, Finak G, et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet 2017; 390: 1511-20.

70. Stitz L, Vogel A, Schnee M, Voss D, Rauch S, Mutzke T, et al. A thermostable messenger RNA

based vaccine against rabies. PLoS Negl Trop Dis 2017; 11: e0006108.

71. Maruggi G, Zhang C, Li J, Ulmer JB, Yu D. mRNA as a transformative technology for vaccine development to control infectious diseases. Mol Ther 2019; 27: 757-72.

72. Kowalski PS, Rudra A, Miao L, Anderson DG. Delivering the messenger: advances in technologies for therapeutic mRNA delivery. Mol Ther 2019; 27: 710-28.

73. Moderna, Inc. Moderna's work on a potential vaccine against COVID-19; Available from: https://www.modernatx.com/modernas-work-potential-vaccine-against-covid-19.

74. Charlton Hume HK, Vidigal J, Carrondo MJT, Middelberg APJ, Roldão A, Lua LHL. Synthetic biology for bioengineering virus-like particle vaccines. Biotechnol Bioeng 2019; 116: 919-35.

75. Liljeroos L, Malito E, Ferlenghi I, Bottomley MJ. Structural and computational biology in the design of immunogenic vaccine antigens. J Immunol Res 2015; 2015: 156241.

76. Yang G, Chen S, Zhang J. Bioinspired and biomimetic nanotherapies for the treatment of infectious diseases. Front Pharmacol 2019; 10: 751.

77. Parodi A, Molinaro R, Sushnitha M, Evangelopoulos M, Martinez JO, Arrighetti N, et al. Bio-inspired engineering of cell- and virus-like nanoparticles for drug delivery. Biomaterials 2017; 147: 155-68.

78. Meyer RA, Sunshine JC, Green JJ. Biomimetic particles as therapeutics. Trends Biotechnol 2015; 33: 514-24.

79. Muth D, Corman VM, Meyer B, Assiri A, Al-Masri M, Farah M, et al. Infectious Middle East respiratory syndrome coronavirus excretion and serotype variability based on live virus isolates from patients in Saudi Arabia. J Clin Microbiol 2015; 53: 2951-5.

80. Yang LT, Peng H, Zhu ZL, Li G, Huang ZT, Zhao ZX, et al. Long-lived effector/central memory T-cell responses to severe acute respiratory syndrome coronavirus (SARS-CoV) S antigen in recovered SARS patients. Clin Immunol. 2006; 120: 171-8.

81. Channappanavar R, Fett C, Zhao J, Meyerholz DK, Perlman S. Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection. J Virol 2014; 88: 11034-44.

82. Wilson-Welder JH, Torres MP, Kipper MJ, Mallapragada SK, Wannemuehler MJ, Narasimhan B. Vaccine adjuvants: current challenges and future approaches. J Pharm Sci 2009; 98: 1278-316.

83. Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends Immunol 2009; 30: 23-32.

84. Perrie Y, Mohammed AR, Kirby DJ, McNeil SE, Bramwell VW. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Int J Pharm 2008; 364: 272-80.

85. Yoo JW, Irvine DJ, Discher DE, Mitragotri S. Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nat Rev Drug Discov 2011; 10: 521-35.

86. Petrovsky N. Comparative safety of vaccine adjuvants: a summary of current evidence and future needs. Drug Saf 2015; 38: 1059-74.

87. López-Sagaseta J, Malito E, Rappuoli R, Bottomley MJ. Self-assembling protein nanoparticles in the design of vaccines. Comput Struct Biotechnol J 2015; 14: 58-68.

88. McNeela EA, Mills KH. Manipulating the immune system: humoral versus cell-mediated immunity. Adv Drug Deliv Rev 2001; 51: 43-54.

89. MacLennan ICM, Toellner K-M, Cunningham AF, Serre K, Sze DMY, Zúñiga E, et al. Extrafollicular antibody responses. Immunol Rev 2003; 194:8-18.

90. Nardelli-Haefliger D, Wirthner D, Schiller JT, Lowy DR, Hildesheim A, Ponci F, et al. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst 2003; 95: 1128-37.

91. Fairfax KA, Kallies A, Nutt SL, Tarlinton DM. Plasma cell development: from B-cell subsets to long-term survival niches. Semin Immunol 2008; 20: 49-58.

92. Kwon YJ, James E, Shastri N, Fréchet JMJ. *In vivo* targeting of dendritic cells for activation of cellular immunity using vaccine carriers based on pH-responsive microparticles. Proc Natl Acad Sci USA 2005; 102: 18264-8.

93. Mellman I. Dendritic cells: master regulators of the immune response. Cancer Immunol Res 2013; 1: 145-9.

94. Peacey M, Wilson S, Perret R, Ronchese F, Ward VK, Young V, et al. Virus-like particles from rabbit hemorrhagic disease virus can induce an anti-tumor response. Vaccine 2008; 26: 5334-7.

95. Schwarz K, Meijerink E, Speiser DE, Tissot AC, Cielens I, Renhof R, et al. Efficient homologous prime-boost strategies for T cell vaccination based on virus-like particles. Eur J Immunol 2005; 35: 816-21.

96. Noad R, Roy P. Virus-like particles as immunogens. Trends Microbiol 2003; 11: 438-44.

97. Hemann EA, Kang SM, Legge KL. Protective CD8 T cell-mediated immunity against influenza A virus infection following influenza virus-like particle vaccination. J Immunol 2013; 191: 2486-94.

98. Smith GE, Flyer DC, Raghunandan R, Liu Y, Wei Z, Wu Y, et al. Development of influenza

H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus. Vaccine 2013; 31: 4305-13.

99. Buonaguro L, Tagliamonte M, Tornesello ML, Buonaguro FM. Developments in virus-like particle-based vaccines for infectious diseases and cancer. Expert Rev Vaccines 2011; 10: 1569-83.

100. Grgacic EVL, Anderson DA. Virus-like particles: passport to immune recognition. Methods 2006; 40: 60-5.

101. Ludwig C, Wagner R. Virus-like particles-universal molecular toolboxes. Curr Opin Biotechnol 2007; 18: 537-45.

102. Bryan JT. Developing an HPV vaccine to prevent cervical cancer and genital warts. Vaccine 2007; 25: 3001-6.

103. Chung YC, Ho MS, Wu JC, Chen WJ, Huang JH, Chou ST, et al. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 2008; 26: 1855-62.

104. Pumpens P, Grens E. The true story and advantages of the famous Hepatitis B virus core particles: outlook 2016. Mol Biol (Mosk) 2016; 50: 558-76.

105. Rodríguez-Limas WA, Sekar K, Tyo KEJ. Virus-like particles: the future of microbial factories and cell-free systems as platforms for vaccine development. Curr Opin Biotechnol 2013; 24: 1089-93.

106. Low JGH, Lee LS, Ooi EE, Ethirajulu K, Yeo P, Matter A, et al. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers. Vaccine 2014; 32: 5041-8.

107. Cai X, Zheng W, Pan S, Zhang S, Xie Y, Guo H, et al. A virus-like particle of the hepatitis B virus preS antigen elicits robust neutralizing antibodies and T cell responses in mice. Antiviral Res 2018; 149: 48-57.

108. Young KR, McBurney SP, Karkhanis LU, Ross TM. Virus-like particles: designing an effective AIDS vaccine. Methods 2006; 40: 98-117.

109. Mohsen MO, Zha L, Cabral-Miranda G, Bachmann MF. Major findings and recent advances in virus-like particle (VLP)-based vaccines. Semin Immunol 2017; 34: 123-32.

110. Maranga L, Cruz PE, Aunins JG, Carrondo MJT. Production of core and virus-like particles with baculovirus infected insect cells. Adv Biochem Eng Biotechnol 2002; 74: 183-206.

111. Liu YV, Massare MJ, Barnard DL, Kort T, Nathan M, Wang L, et al. Chimeric severe acute

respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV. Vaccine 2011; 29: 6606-13.

112. Lu X, Chen Y, Bai B, Hu H, Tao L, Yang J, et al. Immune responses against severe acute respiratory syndrome coronavirus induced by virus-like particles in mice. Immunology 2007; 122: 496-502.

113. Bai B, Hu Q, Hu H, Zhou P, Shi Z, Meng J, et al. Virus-like particles of SARS-like coronavirus formed by membrane proteins from different origins demonstrate stimulating activity in human dendritic cells. PLoS One 2008; 3: e2685.

114. Lokugamage KG, Yoshikawa-Iwata N, Ito N, Watts DM, Wyde PR, Wang N, et al. Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV. Vaccine 2008; 26: 797-808.

115. Lu B, Huang Y, Huang L, Li B, Zheng Z, Chen Z, et al. Effect of mucosal and systemic immunization with virus-like particles of severe acute respiratory syndrome coronavirus in mice. Immunology 2010; 130: 254-61.

116. Hsieh PK, Chang SC, Huang CC, Lee TT, Hsiao CW, Kou YH, et al. Assembly of severe acute respiratory syndrome coronavirus RNA packaging signal into virus-like particles is nucleocapsid dependent. J Virol 2005; 79: 13848-55.

117. Huang Y, Yang ZY, Kong WP, Nabel GJ. Generation of synthetic severe acute respiratory syndrome coronavirus pseudoparticles: implications for assembly and vaccine production. J Virol 2004; 78: 12557-65.

118. Mortola E, Roy P. Efficient assembly and release of SARS coronavirus-like particles by a heterologous expression system. FEBS Lett 2004; 576: 174-8.

119. Ho Y, Lin PH, Liu CYY, Lee SP, Chao YC. Assembly of human severe acute respiratory syndrome coronavirus-like particles. Biochem Biophys Res Commun 2004; 318: 833-8.

120. Novavax, Inc. Novavax advances development of novel COVID-19 vaccine. Available from: http://ir.novavax.com/news-releases/news-release-details/novavax-advances-development-novel-covid-19-vaccine.

121. Wu W, Hsiao SC, Carrico ZM, Francis MB. Genome-free viral capsids as multivalent carriers for taxol delivery. Angew Chem Int Ed Eng. 2009; 48: 9493-7.

122. Braun M, Jandus C, Maurer P, Hammann-Haenni A, Schwarz K, Bachmann MF, et al. Virus-like particles induce robust human T-helper cell responses. Eur J Immunol 2012; 42: 330-40.

123. Wu M, Sherwin T, Brown WL, Stockley PG. Delivery of antisense oligonucleotides to leukemia cells by RNA bacteriophage capsids. Nanomedicine 2005; 1: 67-76.

124. Chaung HC. CpG oligodeoxynucleotides as DNA adjuvants in vertebrates and their applications in immunotherapy. Int Immunopharmacol 2006; 6: 1586-96.

125. Storni T, Ruedl C, Schwarz K, Schwendener RA, Renner WA, Bachmann MF. Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J Immunol 2004; 172: 1777-85.

126. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006; 5: 471-84.

127. Reinis M, Stepanek I, Simova J, Bieblova J, Pribylova H, Indrova M, et al. Induction of protective immunity against MHC class I-deficient, HPV16-associated tumours with peptide and dendritic cell-based vaccines. Int J Oncol 2010; 36: 545-51.

128. Buchanan RM, Popowych Y, Arsic N, Townsend HGG, Mutwiri GK, Potter AA, et al. B-cell activating factor (BAFF) promotes CpG ODN-induced B cell activation and proliferation. Cell Immunol 2011; 271: 16-28.

129. Gallotta M, Assi H, Degagné É, Kannan SK, Coffman RL, Guiducci C. Inhaled TLR9 Agonist renders lung tumors permissive to PD-1 blockade by promoting optimal CD4 and CD8 T-cell interplay. Cancer Res 2018; 78: 4943-56.

130. Terhuja M, Saravanan P, Tamilselvan RP. Comparative efficacy of virus like particle (VLP) vaccine of foot-and-mouth-disease virus (FMDV) type O adjuvanted with poly I:C or CpG in guinea pigs. Biologicals 2015; 43: 437-43.

131. Galarza JM, Latham T, Cupo A. Virus-like particle vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol 2005; 18: 365-72.

132. Fischer NO, Rasley A, Corzett M, Hwang MH, Hoeprich PD, Blanchette CD. Colocalized delivery of adjuvant and antigen using nanolipoprotein particles enhances the immune response to recombinant antigens. J Am Chem Soc 2013; 135: 2044-7.

133. Middelberg APJ, Rivera-Hernandez T, Wibowo N, Lua LHL, Fan Y, Magor G, et al. A microbial platform for rapid and low-cost virus-like particle and capsomere vaccines. Vaccine. 2011; 29: 7154-62.

134. Monteiro F, Bernal V, Chaillet M, Berger I, Alves PM. Targeted supplementation design for improved production and quality of enveloped viral particles in insect cell-baculovirus expression system. J Biotechnol 2016; 233: 34-41.

135. Vicente T, Roldão A, Peixoto C, Carrondo MJT, Alves PM. Large-scale production and purification of VLP-based vaccines. J Invertebr Pathol 2011; 107: S42-8.

136. Ohtaki N, Takahashi H, Kaneko K, Gomi Y, Ishikawa T, Higashi Y, et al. Purification and concentration of non-infectious West Nile virus-like particles and infectious virions using a pseudo-affinity Cellufine Sulfate column. J Virol Methods 2011; 174: 131-5.

137. Lima TM, Souza MO, Castilho LR. Purification of flavivirus VLPs by a two-step chomatographic process. Vaccine 2019; 37: 7061-9.

138. Carvalho SB, Fortuna AR, Wolff MW, Peixoto C, Alves PM, Reichl U, et al. Purification of influenza virus-like particles using sulfated cellulose membrane adsorbers. J Chem Technol Biotechnol 2018; 93: 1988-96.

Figure 1. Immune response to an Ad vector vaccine. When the Ad vector vaccine infects non-APCs, the infected cells express and secrete antigenic proteins, which are taken by antigen-presenting cells (APCs) and B cells. The antigenic proteins are degraded into antigenic peptides. APCs present exogenous antigenic peptides to CD4$^+$ T cells through MHC-II. Cytokines produced by activated CD4$^+$ T cells contribute to the activation of CD8$^+$ T cells. B cells present antigenic peptides to follicular T helper cells through MHC-II, thereby promoting further B cell differentiation into long-lived antibody-producing plasma cells. When the Ad vector vaccine infects APCs, the vaccine expresses the antigen protein which is subsequently digested into antigenic peptides. The antigenic peptides are then presented to CD8$^+$ T cells through MHC-I. In this way, both T cell subsets are activated.

Figure 2. mRNA vaccine-mediated antigen presentation via MHC-I and MHC-II pathways. When an mRNA vaccine is taken by APCs, the antigenic proteins are translated in these cells. These proteins become endogenous proteins and are degraded by the proteasome into small peptides. The peptides are transported to the endoplasmic reticulum and loaded onto MHC-I molecules, and then activate CD8$^+$ T cells through the MHC-I pathway. In the endoplasmic reticulum, MHC-II molecules are protected by an invariant chain (Ii) to prevent them from binding to endogenous peptides. The MHC-II-Ii complex is exported to the fusion vesicle through the Golgi apparatus, and then the invariant chain is replaced by exogenous antigenic peptides. When the vaccine is taken by non-APC cells, it will express and secreted antigenic proteins. These exogenous proteins enter APCs through endocytosis and activate CD4$^+$ T cells through the MHC-II pathway.

Figure 3. Generation of SARS-CoV-2 CpG-VLPs vaccine and the corresponding immune response. VLPs induce humoral immunity through the B cells and cross-presentation. VLPs induce cellular immunity through antigen-presenting cells.

Table 1. Types of traditional vaccines and possible immune responses

Vaccine types	Epitope	Immune response *in vivo*	References
Inactivated vaccine	S, N, M	Induces high levels of neutralizing antibodies elicits systemic humoral immunity.	[10-13]
Live-attenuated vaccine	S	Induces cross-neutralizing antibodies, inducing strong humoral and cellular immune responses.	[14-16]
Viral-vector vaccine	S, N	Induces neutralizing antibodies, induces systemic humoral response and CD8$^+$ T-cell responses.	[17-19]
Subunit vaccine	S1, RBD	Induces a high titer of neutralizing antibodies, elicits systemic humoral immune responses.	[20, 21]
Nucleic acid vaccine	S, S1	Both nucleic acid vaccine encoding S and S1 proteins induced neutralizing antibodies, only the latter demonstrated significant specific cellular immune response.	[22, 23]

S: spike protein; N: nucleocapsid protein; M: membrane protein; S1: spike protein S1 subunit; RBD: receptor binding domain.

Graphical Abstract

Coronavirus vaccine development. COVID-19 is encoded by single-stranded RNA and consists of spike proteins, nucleocapsid proteins, envelope proteins, and membrane proteins. Among them, spike proteins are composed of S1 and S2 subunits, and the receptor binding domain is located on the S1 protein. Coronavirus vaccine development from conventional vaccine to biomimetic nanotechnology vaccine.